Arbutus Biopharma
ABUS
71 hedge funds and large institutions have $92.6M invested in Arbutus Biopharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 25 closing their positions.
29% more call options, than puts
Call options by funds: $798K | Put options by funds: $621K
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0.21% more ownership
Funds ownership: 43.35% → 43.56% (+0.21%)
19% less funds holding
Funds holding: 88 → 71 (-17)
59% less capital invested
Capital invested by funds: $227M → $92.6M (-$135M)
64% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.1M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.46M |
| 3 |
RI
RTW Investments
New York
|
+$1.24M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.22M |
| 5 |
B
Bailard
Foster City,
California
|
+$719K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.39M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.7M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.24M |
| 4 |
Jennison Associates
New York
|
-$2.55M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.56M |
ABUS Hedge Fund Activity: Q4 2018 in Review
71 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2018, worth a combined $92.6M — down 59% from $227M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ABUS and 9 opened new positions — a net loss of 16 holders — while 20 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, adding an estimated $10.1M. The largest seller was Foresite Capital Management IV, cutting an estimated $5.39M.
- 71 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2018, down from 88 in Q3 2018.
- Funds reported $92.6M of Arbutus Biopharma stock for Q4 2018, down 59% quarter-over-quarter.
- 9 funds opened new Arbutus Biopharma positions in Q4 2018 and 25 closed out, a net change of -16 holders.
- The largest Arbutus Biopharma buyer in Q4 2018 was EcoR1 Capital, an estimated $10.1M added.
- The largest Arbutus Biopharma seller in Q4 2018 was Foresite Capital Management IV, an estimated $5.39M sold.
Based on aggregated 13F filings for Q4 2018.